Skip to main content
SpringerLink
Log in

Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections

  • Review
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Tumour necrosis factor-α (TNF) and interleukin-1β (IL-1β) are the central mediators in the genesis of sepsis. The proinflammatory effects of these cytokines are counteracted in vivo by natural inhibitors. Soluble TNF receptors (sTNFR) are shed upon inflammatory stimuli such as IL-1β and TNF itself. Circulating TNF can be complexed by these receptors, thus preventing TNF from binding to effector cells. The binding of IL-1β to its receptor can be blocked by high concentrations of interleukin-1 receptor antagonist (IL-1Ra), which is produced and released upon nearly the same stimuli as IL-1β. This review presents some aspects of the kinetic behaviour of native sTNFR and of the production of native IL-1Ra during severe infections. It appears that in fulminant septicaemia, the plasma concentration of TNF is increased only transiently, during the very early stage of the infection. The concentration of sTNFR, in contrast, remains elevated much longer, probably due to a slower clearance. During the acute stage of severe infectious diseases, peripheral blood cells cannot be stimulated to produce IL-1β. The production of IL-1Ra, in contrast, is not affected. Thus, the kinetic behaviour and regulation of TNF and IL-1β, is different from that of their antiinflammatory counterparts.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dinarello CA: The proinflammatory cytokines interleukin-1 and tumor necrosis factor and the treatment of the septic shock syndrome. Journal of Infectious Diseases 1991, 163: 1177–1184.

    CAS  PubMed  Google Scholar 

  2. Van Deuren M, Dofferhoff ASM, Van der Meer JWM: Cytokines and the response to infection. Journal of Pathology 1992, 168: 349–356.

    Article  PubMed  Google Scholar 

  3. Waage A, Halstensen A, Espevik T: Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987, i: 355–357.

    Article  Google Scholar 

  4. Girardin E. Grau GE, Dayer JM, Roux-Lobard P, Lambert PH, andthe J5 Study Group: Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. New England Journal of Medicine 1988, 39: 397–400.

    Article  Google Scholar 

  5. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. Journal of Experimental Medicine 1989, 169: 333–338.

    Article  CAS  PubMed  Google Scholar 

  6. Hesse DG, Trace KJ, Fong Y, Manogue KR, Palladino MA, Cerami A, Shires T, Lowry SF: Cytokine appearance in human endotoxemia and primate bacteremia. Surgery, Gynecology and Obstetrics 1988, 166: 147–153.

    CAS  PubMed  Google Scholar 

  7. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. New England Journal of Medicine 1988, 318: 1481–1486.

    Article  CAS  PubMed  Google Scholar 

  8. Cannon JG, Tompkins RG, Gelfland GA, Michie HR, Stanford GG, Van der Meer JWM, Endres S, Lonneman G, Corsetti J, Chernow C, Wilmore DW, Wolf SM, Burke JF, Dinarello CA: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. Journal of Infectious Diseases 1990, 161: 79–84.

    CAS  PubMed  Google Scholar 

  9. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parillo JE: The cardiovascular response of normal humans to the administration of endotoxin. New England Journal of Medicine 1989, 321: 280–287.

    Article  CAS  PubMed  Google Scholar 

  10. Van der Poll T, Büller HR, Ten Cate H, Wortel CH, Baure KA, Van Deventer SJH, Hack E, Sauerwein HP, Rosenberg RD, Ten Cate JW: Activation of coagulation after administration of tumor necrosis factor to normal subjects. New England Journal of Medicine 1990, 322: 1622–1627.

    Article  PubMed  Google Scholar 

  11. Okusawa S, Gelfland JA, Ikejima T, Conolly RJ, Dinarello CA: Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. Journal of Clinical Investigation 1988, 81: 1162–1172.

    CAS  PubMed  Google Scholar 

  12. Beutler B, Milsark IW, Cerami AC: Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985, 229: 869–871.

    CAS  PubMed  Google Scholar 

  13. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT Kuo GC, Lowry SF, Cerami A: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987, 330: 662–665.

    Article  CAS  PubMed  Google Scholar 

  14. Ohlsson K, Björk P, Bergenfeldt M, Hageman R, Thompson RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990, 348: 550–552.

    Article  CAS  PubMed  Google Scholar 

  15. Alexander HR, Doherty GM, Buresh CM, Venzon DJ, Norton JA: A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. Journal of Experimental Medicine 1991, 173: 1029–1032.

    Article  CAS  PubMed  Google Scholar 

  16. Blanchard DK, Djeu JY, Klein TW, Friedman H, Stewart WE: Protective effects of tumor necrosis factor in experimentalLegionella pneumophila infections of mice via activation of PMN function. Journal of Leukocyte Biology 1988, 43: 429–435.

    CAS  PubMed  Google Scholar 

  17. Matsiota-Bernard P, Léfèbre C, Sedqui M, Cornillet P, Guenounou M: Involvement of tumor necrosis factor alpha in intracellular multiplication ofLegionella pneumophila in human monocytes. Infection and Immunity 1993, 61: 4980–4983.

    CAS  PubMed  Google Scholar 

  18. Havell EA: Production of tumor necrosis factor during murine listeriosis. Journal of Immunology 1987, 139: 4225–4231.

    CAS  Google Scholar 

  19. Brandtzaeg P, Halstensen A, Kierulf P, Espevik T, Waage A: Molecular mechanisms in the compartmentalized inflammatory response presenting as meningococcal meningitis or septic shock. Microbial Pathogenesis 1992, 13: 423–431.

    Article  CAS  PubMed  Google Scholar 

  20. Chapman PB, Lester TJ, Casper ES, Gabrilove JL, Wong GY, Kempin SJ, Gold PJ, Welt S, Warren RS, Starnes F, Sherwin SA, Old LJ, Oettgen HF: Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. Journal of Clinical Oncology 1987, 5: 1942–1951.

    CAS  PubMed  Google Scholar 

  21. Marks JD, Berman Marks C, Luce JM, Montgomery B, Turner J, Metz CA, Murray JF: Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednisolone administration. American Review of Respiratory Disease 1990, 141: 94–97.

    CAS  PubMed  Google Scholar 

  22. Olsson I, Gullberg U, Lantz M, Peetre C: A tumor necrosis factor binding protein (TNF-BP)-physiological antagonist of TNF. Biotherapy 1991, 3: 159–165.

    Article  CAS  PubMed  Google Scholar 

  23. Wallach D, Engelmann H, Nophar Y, Aderka D, Kemper O, Hornik V, Holtman H, Brakebusch C: Soluble and cell surface receptors for tumor necrosis factor. Agent and Actions 1991, 35: Supplement 51–57.

    CAS  Google Scholar 

  24. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D: Stabilisation of the bioactivity of tumor necrosis factor by its soluble receptors. Journal of Experimental Medicine 1992, 175: 323–329.

    Article  CAS  PubMed  Google Scholar 

  25. Arend WP: Interleukin-1 receptor antagonist. A new member of the interleukin 1 family. Journal of Clinical Investigation 1991, 88: 1445–1451.

    Article  CAS  PubMed  Google Scholar 

  26. Granowitz EV, Santos AA, Poutsiaka DD, Cannon JG, Wilmore DW, Wolff SM, Dinarello CA: Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet 1991, 338: 1423–1424.

    Article  CAS  PubMed  Google Scholar 

  27. Poutsiaka DD, Clark BD, Vannier E, Dinarello CA: Production of interleukin-1 receptor antagonist and interleukin-1β by peripheral blood mononuclear cells is differentially regulated. Blood 1991, 78: 1275–1281.

    CAS  PubMed  Google Scholar 

  28. Vannier E, Miller LC, Dinarello CA: Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist. Proceedings of the National Academy of Science of the USA 1992, 89: 4076–4080.

    CAS  Google Scholar 

  29. Fischer CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emanuel G, Ng D, Bloedow DC, Catalano MA, andthe IL-1Ra Sepsis Syndrome Study Group: Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open label, placebo-controlled multicenter trial. Critical Care Medicine 1994, 22: 12–21.

    Google Scholar 

  30. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D, Franchimont P, Lamy M: Cytokine serum level during severe sepsis in humans. Il-6 as a marker of severity. Annals of Surgery 1992, 215: 356–362.

    Article  CAS  PubMed  Google Scholar 

  31. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P: Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Critical Care Medicine 1989, 17: 975–978.

    CAS  PubMed  Google Scholar 

  32. Debets JMH, Kampmeijer R, Van der Linden MPMH, Buurman WA, Van der Linden CJ: Plasma tumor necrosis factor and mortality in critically ill septic patients. Critical Care Medicine 1989, 17: 489–494.

    CAS  PubMed  Google Scholar 

  33. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF: Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor α in vitro and in vivo. Proceedings of the National Academy of Sciences of the USA 1992, 89: 4845–4849.

    PubMed  Google Scholar 

  34. Girardin E, Roux-Lombard P, Grau GE, Suter P, Gallati H, Dayer M, andthe J5 Study Group: Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 1992, 76: 20–23.

    CAS  PubMed  Google Scholar 

  35. Bemelmans MHA, Gouma DJ, Buurman WA: Influence of nephrectomy on tumor necrosis factor clearance in a murine model. Journal of Immunology 1993, 150: 2007–2017.

    CAS  Google Scholar 

  36. Bjorvatn B, Bjertnaes L, Fadnes HO, Flaegstad T, Gutteberg TJ, Kristiansen BE, Pape J, Rekvig OP, Østerud B, Aanderud L: Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. British Medical Journal 1984, 288: 439–441.

    Article  CAS  PubMed  Google Scholar 

  37. Van Deuren M, Santman FW, Van Dalen R, Sauerwein RW, Span LFR, Van der Meer JWM: Plasma exchange and whole blood exchange in meningococcal sepsis. Clinical Infectious Diseases 1992, 15: 424–430.

    PubMed  Google Scholar 

  38. Calandra T, Baumgartner J-D, Grau GE, Wu M-M, Lambert PH, Schellekens J, Verhoef J, Glauser MP, andthe Swiss-Dutch J5 Immunoglobin Study Group: Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-gamma in the serum of patients with septic shock. Journal of Infectious Diseases 1990, 161: 982–987.

    CAS  PubMed  Google Scholar 

  39. Dinarello CA, Cannon JG: Cytokine measurements in septic shock. Annals of Internal Medicine 1993, 119: 83–84.

    Google Scholar 

  40. Van Deuren M, Van der Ven-Jongekrijg J, Demacker PMN, Van der Meer JWM: Cytokine production in whole blood cultures. Journal of the International Federation of Clinical Chemistry 1993, 5: 216–221.

    Google Scholar 

  41. Van Deuren M, Van der Ven-Jongekrijg J, Demacker PMN, Bartelink AKM, Van Dalen R, Sauerwein RW, Gallati H, Vannice JL, Van der Meer JWM: Differential expression of proinflammatory cytokines and their inibitors during the course of meningococcal infections. Journal of Infectious Diseases 1994, 169: 157–161.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University Hospital Nijmegen, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

    M. van Deuren

Authors
  1. M. van Deuren
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Deuren, M. Kinetics of tumour necrosis factor-alpha, soluble tumour necrosis factor receptors, interleukin 1-beta and its receptor antagonist during serious infections. Eur. J. Clin. Microbiol. Infect. Dis. 13 (Suppl 1), S12–S16 (1994). https://doi.org/10.1007/BF02390680

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02390680

Keywords

Search

Navigation